Symptom cluster analyses based on symptom occurrence and severity ratings among pediatric oncology patients during myelosuppressive chemotherapy

Cancer Nursing

Volumn 35, Issue 1, 2012, Pages 19-28

  Baggott, Christina ^a   Cooper, Bruce A ^a   Marina, Neyssa ^b   Matthay, Katherine K ^c   Miaskowski, Christine ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Pediatric; Symptom clusters

Indexed keywords

ADOLESCENT; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLUSTER ANALYSIS; CONCEPTUAL FRAMEWORK; DISEASE SEVERITY; FACTORIAL ANALYSIS; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORIAL SYMPTOM ASSESSMENT SCALE; MOOD DISORDER; NEUROPSYCHOLOGY; PRIORITY JOURNAL; RATING SCALE; RECALL; REVIEW; RISK FACTOR; SCHOOL CHILD; SOCIAL ASPECT; SYMPTOMATOLOGY;

ADAPTATION, PSYCHOLOGICAL; ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CLUSTER ANALYSIS; CROSS-SECTIONAL STUDIES; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KARNOFSKY PERFORMANCE STATUS; MALE; MOOD DISORDERS; NEOPLASMS; SELF REPORT; SEVERITY OF ILLNESS INDEX;

EID: 84857032989     PISSN: 0162220X     EISSN: 15389804     Source Type: Journal    
DOI: 10.1097/NCC.0b013e31822909fd     Document Type: Review

References (58)

1. Docherty SL. Symptom experiences of children and adolescents with cancer. Annu Rev Nurs Res. 2003;21:123-149.
2. Baggott C, Dodd M, Kennedy C, Marina N, Miaskowski C. Multiple symptoms in pediatric oncology patients: a systematic review. J Pediatr Oncol Nurs. 2009;26(6):325-339.
3. Collins JJ, Byrnes ME, Dunkel IJ, et al. The measurement of symptoms in children with cancer. J Pain Symptom Manage. 2000;19(5): 363-377. (Pubitemid 30408303)
4. Hedström M, Haglund K, Skolin I, von Essen L. Distressing events for children and adolescents with cancer: child, parent, and nurse perceptions. J Pediatr Oncol Nurs. 2003;20(3):120-132. (Pubitemid 38251128)
5. Yeh CH, Chiang YC, Chien LC, Lin L, Yang CP, Chuang HL. Symptom clustering in older Taiwanese children with cancer. Oncol Nurs Forum. 2008;35(2):273-281.
6. Baggott C, Dodd M, Kennedy C, et al. Changes in children's reports of symptom occurrence and severity during a course of myelosuppressive chemotherapy. J Pediatr Oncol Nurs. 2010.
7. Walker AJ, Gedaly-Duff V, Miaskowski C, Nail L.Differences in symptom occurrence, frequency, intensity, and distress in adolescents prior to and one week after the administration of chemotherapy. J Pediatr Oncol Nurs. 2010; 27(5):259-265.
8. Tseng TH, Cleeland CS, Wang XS, Lin CC. Assessing cancer symptoms in adolescents with cancer using the Taiwanese version of the M. D. Anderson Symptom Inventory. Cancer Nurs. 2008;31(3):E9-16. (Pubitemid 351652225)
9. Hockenberry MJ, Hooke MC, Gregurich M, McCarthy K, Sambuco G, Krull K. Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide. Oncol Nurs Forum. 2010;37(1):E16-27.
10. Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum. 2001; 28(3):465-470.
11. Skerman HM, Yates PM, Battistutta D. Multivariate methods to identify cancer-related symptom clusters. Res Nurs Health. 2009;32(3):345-360.
12. Miaskowski C, Aouizerat BE, Dodd M, Cooper B. Conceptual issues in symptom clusters research and their implications for quality-of-life assessment in patients with cancer. J Natl Cancer Inst Monogr. 2007;(37):39-46.
13. Hattis D, Ginsberg G, Sonawane B, et al. Differences in pharmacokinetics between children and adultsVII. Children's variability in drug elimination half-lives and in some parameters needed for physiologically based pharmacokinetic modeling. Risk Anal. 2003;23(1):117-142. (Pubitemid 36255427)
14. American Cancer Society. Cancer Facts and Figures 2009. 2009. http://www.cancer.org/downloads/STT/500809web.pdf. Accessed January 2, 2011.
15. Hallbook H, Gustafsson G, Smedmyr B, Soderhall S, Heyman M. Treatment outcome in young adults and children 910 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006;107(7):1551-1561. (Pubitemid 44546916)
16. Landrigan PJ, Trasande L, Thorpe LE, et al. The National Children's Study: a 21-year prospective study of 100,000 American children. Pediatrics. 2006;118(5):2173-2186. (Pubitemid 46393701)
17. Humphreys J, Lee KA, Carrieri-Kohlman V, et al. A middle range theory of symptom management. In: Smith MJ, Liehr PR, eds. Middle Range Theory for Nursing. New York: Springer Publishing Company; 2008: 145-158.
18. Karnofsky D, Burchenal J. The clinical evaluation of chemotherapeutics in cancer. In: Macleod CM, ed. Evaluation of Chemotherapeutic Agents; Symposia of the Section on Microbiology, The New York Academy of Medicine. New York: Columbia Univ. Press; 1949:191-205.
19. Acquadro C, Conway K, Girourdet C, Mear I. Linguistic Validation Manual for Patient-Reported Outcomes (PRO) Instruments. Lyon, France: Mapi Research Institute; 2004.
20. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A(9):1326-1336. (Pubitemid 24322071)
21. Kim E, Jahan T, Aouizerat BE, et al. Changes in symptom clusters in patients undergoing radiation therapy. Support Care Cancer. 2009.
22. Schaafsma J, Osoba D. The Karnofsky Performance Status scale reexamined: a cross-validation with the EORTC-C30. Qual Life Res. 1994; 3(6):413-424.
23. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187-193. (Pubitemid 14138407)
24. Forinder U, Lof C, Winiarski J. Quality of life following allogeneic stem cell transplantation, comparing parents' and children's perspective. Pediatr Transplant. 2006;10(4):491-496. (Pubitemid 43780684)
25. Jalali R, Dutta D, Kamble R, et al. Prospective assessment of activities of daily living using modified Barthel's Index in children and young adults with low-grade gliomas treated with stereotactic conformal radiotherapy. J Neurooncol. 2008;90(3):321-328.
26. Williams PD, Schmideskamp J, Ridder EL, Williams AR. Symptom monitoring and dependent care during cancer treatment in children: pilot study. Cancer Nurs. 2006;29(3):188-197. (Pubitemid 44309578)
27. Muthén LK, Muthén BO. Mplus (Version 6.0). Lons Angeles, CA: Muthén and Muthén; 2010.
28. Muthén BO. Goodness of fit with categorical and other nonnormal variables. In: Bollen KA, Long JS, eds. Testing Structural Equation Models. Thousand Oaks, CA: Sage; 1993:205-234.
29. Muthén B. A general structural equation model with dichotomous, ordered categorical, and continuous latent variable indicators. Psychometrika. 1984;49(1):115-132.
30. Beauducel A, Herzberg PY. On the performance of maximum likelihood versus means and variance adjusted weighted least squares estimation in CFA. Struct Equat Model. 2006;13(2):186-203. (Pubitemid 43812907)
31. Browne MW. An overview of analytic rotation in exploratory factor analysis. Multivariate Behav Res. 2001;36(1):111-150.
32. Muthén LK, Muthén BO. Mplus User's Guide. 6th ed. Los Angeles, CA: Muthén & Muthén; 1998-2010.
33. Muthén LK, Muthén BO. Mplus (Version 6.1). Los Angeles, CA: Muthén & Muthén; 2010.
34. Yates A.Multivariate Exploratory Data Analysis: A Perspective on Exploratory Factor Analysis. Albany, NY: State University of New York Press; 1987.
35. Brown TA. Confirmatory Factor Analysis for Applied Research. New York: Guilford Press; 2006.
36. Hu L-T, Bentler PM. Evaluating model fit. In: Hoyle RH, ed. Structural Equation Modeling: Concepts, Issues, and Applications. Thousand Oaks, CA: Sage; 1995.
37. Bentler PM. Comparative fit indexes in structural models. Psychol Bull. 1990;107(2):238-246.
38. Hu L-T, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equat Model. 1999;61(1):1-55.
39. Browne MW, Cudeck R. Alternative ways of assessing model fit. In: Bollen KA, Long JS, eds. Testing Structural Equation Models. Thousand Oaks, CA: Sage; 1993:137-162.
40. Comrey AL, Lee HB. A First Course in Factor Analysis. 2nd ed. Mahwah, NJ: Lawrence Erlbaum Publications; 1992.
41. Pett MA, Lackey NR, Sullivan JJ. Making Sense of Factor Analysis: The Use of Factor Analysis for Instrument Development in Health Care Research. Thousand Oaks, CA: Sage; 2003.
42. Marsh HW, Muthén B, Asparouhov T, et al. Exploratory structural equation modeling, integrating CFA and EFA: application to students' evaluations of university teaching. Struct Equat Model. 2009;16(3):439-476.
43. Gerbing DW, Hamilton JG. Viability of exploratory factor analysis as a precursor to confirmatory factor analysis. Struct Equat Model. 1996;3(1): 62-72.
44. Costello AB, Osborne JW. Best practices in exploratory factor analysis: four recommendations for getting the most from your analysis [computer file]. Pract Assess Res Eval. 2005;10:1-9.
45. Kline RB. Principles and Practice of Structural Equation Modeling. 3rd ed. New York: Guilford Press; 2011.
46. Jackson DL. Revisiting sample size and number of parameter estimates: some support for the N:q hypothesis. Struct Equat Model. 2003;10(1):128-141.
47. Nunnally JC, Bernstein IH. Psychometric Theory. 3rd ed. New York: McGraw-Hill; 1994.
48. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokineimmunologic model of cancer symptoms. Cancer. 2003;97(11):2919-2925. (Pubitemid 36605163)
49. Lee BN, Dantzer R, Langley KE, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;11(5):279-292. (Pubitemid 39194326)
50. Aubert A, Dantzer R. The taste of sickness: lipopolysaccharide-induced finickiness in rats. Physiol Behav. 2005;84(3):437-444. (Pubitemid 40342598)
51. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000; 89(7):1634-1646.
52. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs. 1978;1(5):373-378.
53. Aprile G, Ramoni M, Keefe D, Sonis S. Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer. 2008;112(2):284-292.
54. Skerman HM, Yates PM, Battistutta D. Cancer-related symptom clusters for symptom management in outpatients after commencing adjuvant chemotherapy, at 6 months, and 12 months. Support Care Cancer. 2011.
55. Yamagishi A, Morita T, Miyashita M, Kimura F. Symptom prevalence and longitudinal follow-up in cancer outpatients receiving chemotherapy. J Pain Symptom Manage. 2009;37(5):823-830.
56. Kim E, Jahan T, Aouizerat BE, et al. Differences in symptom clusters identified using occurrence rates versus symptom severity ratings in patients at the end of radiation therapy. Cancer Nurs. 2009;32(6):429-436.
57. Suwisith N, Hanucharunkul S, Dodd M, Vorapongsathorn T, Pongthavorakamol K, Asavametha N. Symptom clusters and functional status of women with breast cancer. Thai J Nurs Res. 2008;12(3):153-164.
58. Dodd MJ, Janson S, Facione N, et al. Advancing the science of symptom management. J Adv Nurs. 2001;33(5):668-676. (Pubitemid 33614460)